Anthrax laboratory findings: Difference between revisions
Joao Silva (talk | contribs) |
m (Bot: Removing from Primary care) |
||
(31 intermediate revisions by 5 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Anthrax}} | {{Anthrax}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{JS}} | ||
==Overview== | ==Overview== | ||
Initial evaluation of patients suspected of having anthrax should be similar to the standard evaluation for patients with an acute [[febrile]] illness and should have an emphasis on obtaining pre-treatment blood and other appropriate cultures.<ref name=CDC>{{cite web | title = Centers for Disease Control and Prevention Expert Panel Meetings on Prevention and Treatment of Anthrax in Adults | url = http://wwwnc.cdc.gov/eid/article/20/2/13-0687_article }}</ref> When systemic anthrax is present, abnormalities in laboratory tests include [[anemia]], [[thrombocytopenia]], and [[leukocytosis]] particularly in the latter stages of the disease. Other laboratory findings are [[hyponatremia]], increased [[BUN]], elevated [[transaminase]] levels, [[hypoalbuminemia]], and elevated [[troponin]]. Cell cultures from the initial skin lesion, [[blood]], [[CSF]], or [[pleural fluid]] can identify the [[Bacillus anthracis|organism]] and possibly the [[toxins]]. In injection anthrax, the typical laboratory finding is an [[inflammatory]] pattern with a low [[CRP]]. A normal [[PT]]/[[PTT]] at admission does not exclude [[coagulopathy]] nor [[DIC]]. | |||
==Laboratory Findings== | ==Laboratory Findings== | ||
Show below is a table depicting the tests are used in the [[diagnosis]] and monitoring of systemic [[anthrax]].<ref name="HendricksWright2014">{{cite journal|last1=Hendricks|first1=Katherine A.|last2=Wright|first2=Mary E.|last3=Shadomy|first3=Sean V.|last4=Bradley|first4=John S.|last5=Morrow|first5=Meredith G.|last6=Pavia|first6=Andy T.|last7=Rubinstein|first7=Ethan|last8=Holty|first8=Jon-Erik C.|last9=Messonnier|first9=Nancy E.|last10=Smith|first10=Theresa L.|last11=Pesik|first11=Nicki|last12=Treadwell|first12=Tracee A.|last13=Bower|first13=William A.|title=Centers for Disease Control and Prevention Expert Panel Meetings on Prevention and Treatment of Anthrax in Adults|journal=Emerging Infectious Diseases|volume=20|issue=2|year=2014|issn=1080-6040|doi=10.3201/eid2002.130687}}</ref> | |||
{| style="border: 2px solid #DCDCDC; font-size: 90%" | {| style="border: 2px solid #DCDCDC; font-size: 90%" | ||
|+ '''Laboratory findings''' | |+ '''Laboratory findings''' | ||
|- | |- | ||
! style="width: | ! style="width: 150px; background: #4479BA; text-align: center;"|{{fontcolor|#FFF|Test}} | ||
! style="width: 200px; background: #4479BA; text-align: center;"| {{fontcolor|#FFF| Initial Findings}} | ! style="width: 200px; background: #4479BA; text-align: center;"| {{fontcolor|#FFF|Initial Findings}} | ||
! style="width: 200px; background: #4479BA; text-align: center;"| {{fontcolor|#FFF| Serial Monitoring}} | ! style="width: 200px; background: #4479BA; text-align: center;"| {{fontcolor|#FFF|Serial Monitoring}} | ||
|- | |- | ||
| style="background: #F5F5F5; padding: 5px; text-align: center;"| ''' | | style="background: #F5F5F5; padding: 5px; text-align: center;"| '''CBC''' | ||
| style="background: #DCDCDC; padding: 5px;"| [[Hemoconcentration]]<br>Possible [[ | | style="background: #DCDCDC; padding: 5px;"| [[Hemoconcentration]]<br>Possible [[thrombocytopenia]]<br>[[Leukocyte]] count commonly normal | ||
| style="background: #DCDCDC; padding: 5px;"| [[Anemia]]<br>[[Thrombocytopenia]]<br>[[Leukocytosis]] (late in disease) | | style="background: #DCDCDC; padding: 5px;"| [[Anemia]]<br>[[Thrombocytopenia]]<br>[[Leukocytosis]] (late in disease) | ||
|- | |- | ||
| style="background: #F5F5F5; padding: 5px; text-align: center;"| ''' | | style="background: #F5F5F5; padding: 5px; text-align: center;"| '''Electrolyte<br>Renal Panel''' | ||
| style="background: #DCDCDC; padding: 5px;"| Decreased | | style="background: #DCDCDC; padding: 5px; text-align: center;" colspan=2| Decreased sodium level<br>Increased [[BUN]] | ||
|- | |- | ||
| style="background: #F5F5F5; padding: 5px; text-align: center;"| ''' | | style="background: #F5F5F5; padding: 5px; text-align: center;"| '''Liver Enzymes<br>Serum Albumin''' | ||
| style="background: #DCDCDC; padding: 5px;"|Elevated [[transaminase]] levels<br>[[ | | style="background: #DCDCDC; padding: 5px; text-align: center;" colspan=2| Elevated [[transaminase]] levels<br>[[Hypoalbuminemia]] | ||
|- | |- | ||
| style="background: #F5F5F5; padding: 5px; text-align: center;"| ''' | | style="background: #F5F5F5; padding: 5px; text-align: center;"| '''PT<br>PTT<br>D-dimer<br>Fibrinogen''' | ||
| style="background: #DCDCDC; padding: 5px;"| Normal [[PT]]/[[PTT]] does not exclude [[DIC]] or [[coagulopathy]] | | style="background: #DCDCDC; padding: 5px;"| Normal [[PT]]/[[PTT]] does not exclude [[DIC]] or [[coagulopathy]] | ||
| style="background: #DCDCDC; padding: 5px;"| Low threshold for hypercoagulability workup:<br>[[Haptoglobin]]<br>[[LDH]]<br>[[Fibrin]] split products<br>ADAMTS 13 if [[hemolytic anemia]] | | style="background: #DCDCDC; padding: 5px;"| Low threshold for hypercoagulability workup:<br>[[Haptoglobin]]<br>[[LDH]]<br>[[Fibrin]] split products<br>ADAMTS 13 if [[hemolytic anemia]] | ||
|- | |- | ||
| style="background: #F5F5F5; padding: 5px; text-align: center;"| ''' | | style="background: #F5F5F5; padding: 5px; text-align: center;"| '''C-Reactive Protein''' | ||
| style="background: #DCDCDC; padding: 5px;"| Characterization of | | style="background: #DCDCDC; padding: 5px; text-align: center;" colspan=2| Characterization of inflammatory response<br>Typically low [[CRP]] in injection [[anthrax]] | ||
| style="background: #DCDCDC; padding: 5px;"| | |- | ||
| style="background: #F5F5F5; padding: 5px; text-align: center;"| '''Gram stain<br>Cultures<br>Toxic Assays'''<br><span style="font-size:90%">([[Blood]], [[serum]], [[CSF]], [[pleural fluid]], [[ascites]], wound [[exudate]]*, bronchial [[exudate]])</span> | |||
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan=2| Cultures usually negative after [[antibiotics]]<br>[[Toxins]] may be detected | |||
|- | |- | ||
| style="background: #F5F5F5; padding: 5px; text-align: center;"| ''' | | style="background: #F5F5F5; padding: 5px; text-align: center;"| '''Cardiac Enzymes<br>BNP''' | ||
| style="background: #DCDCDC; padding: 5px;"| [[ | | style="background: #DCDCDC; padding: 5px; text-align: center;" colspan=2| [[Troponin]] leak caused by increased [[cardiac]] demand from [[infection]]<br>(particularly if [[atrial fibrillation]] with rapid [[ventricular]] response) | ||
|} | |} | ||
<nowiki>*</nowiki> Note that topical swabs from skin lesions will not pick up [[B. anthracis]]. Detection in smears or by culture requires lifting the edge of the eschar with tweezers (this gives no pain unless there is secondary infection) and obtaining fluid from underneath. The fluid will probably be sterile if the patient has been treated with an [[antibiotic]]. | |||
==References== | ==References== | ||
Line 45: | Line 46: | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category: | [[Category:Disease]] | ||
[[Category:Bacterial diseases]] | |||
[[Category:Biological weapons]] | |||
[[Category:Livestock]] | |||
[[Category:Zoonoses]] | |||
[[Category:Medical disasters]] | |||
[[Category:Emergency mdicine]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] | |||
[[Category:Dermatology]] | |||
[[Category:Pulmonology]] | |||
[[Category:Gastroenterology]] |
Latest revision as of 20:25, 29 July 2020
Anthrax Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Anthrax laboratory findings On the Web |
American Roentgen Ray Society Images of Anthrax laboratory findings |
Risk calculators and risk factors for Anthrax laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Initial evaluation of patients suspected of having anthrax should be similar to the standard evaluation for patients with an acute febrile illness and should have an emphasis on obtaining pre-treatment blood and other appropriate cultures.[1] When systemic anthrax is present, abnormalities in laboratory tests include anemia, thrombocytopenia, and leukocytosis particularly in the latter stages of the disease. Other laboratory findings are hyponatremia, increased BUN, elevated transaminase levels, hypoalbuminemia, and elevated troponin. Cell cultures from the initial skin lesion, blood, CSF, or pleural fluid can identify the organism and possibly the toxins. In injection anthrax, the typical laboratory finding is an inflammatory pattern with a low CRP. A normal PT/PTT at admission does not exclude coagulopathy nor DIC.
Laboratory Findings
Show below is a table depicting the tests are used in the diagnosis and monitoring of systemic anthrax.[2]
Test | Initial Findings | Serial Monitoring |
---|---|---|
CBC | Hemoconcentration Possible thrombocytopenia Leukocyte count commonly normal |
Anemia Thrombocytopenia Leukocytosis (late in disease) |
Electrolyte Renal Panel |
Decreased sodium level Increased BUN | |
Liver Enzymes Serum Albumin |
Elevated transaminase levels Hypoalbuminemia | |
PT PTT D-dimer Fibrinogen |
Normal PT/PTT does not exclude DIC or coagulopathy | Low threshold for hypercoagulability workup: Haptoglobin LDH Fibrin split products ADAMTS 13 if hemolytic anemia |
C-Reactive Protein | Characterization of inflammatory response Typically low CRP in injection anthrax | |
Gram stain Cultures Toxic Assays (Blood, serum, CSF, pleural fluid, ascites, wound exudate*, bronchial exudate) |
Cultures usually negative after antibiotics Toxins may be detected | |
Cardiac Enzymes BNP |
Troponin leak caused by increased cardiac demand from infection (particularly if atrial fibrillation with rapid ventricular response) |
* Note that topical swabs from skin lesions will not pick up B. anthracis. Detection in smears or by culture requires lifting the edge of the eschar with tweezers (this gives no pain unless there is secondary infection) and obtaining fluid from underneath. The fluid will probably be sterile if the patient has been treated with an antibiotic.
References
- ↑ "Centers for Disease Control and Prevention Expert Panel Meetings on Prevention and Treatment of Anthrax in Adults".
- ↑ Hendricks, Katherine A.; Wright, Mary E.; Shadomy, Sean V.; Bradley, John S.; Morrow, Meredith G.; Pavia, Andy T.; Rubinstein, Ethan; Holty, Jon-Erik C.; Messonnier, Nancy E.; Smith, Theresa L.; Pesik, Nicki; Treadwell, Tracee A.; Bower, William A. (2014). "Centers for Disease Control and Prevention Expert Panel Meetings on Prevention and Treatment of Anthrax in Adults". Emerging Infectious Diseases. 20 (2). doi:10.3201/eid2002.130687. ISSN 1080-6040.